GlassScriptPhysician profile
Steven M Archer
NPI 1255325353
$5,540.10
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $1,051 · 2021: $1,454 · 2022: $1,298 · 2023: $81.72 · 2024: $50.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $776.67 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $726.00 | 2019-2022 | |
| Abbvie INC. | $531.47 | 2019-2023 | Vraylar |
| Lilly USA, LLC | $338.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $228.64 | 2019-2022 | |
| Pfizer INC. | $226.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $199.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $196.07 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $159.77 | 2019-2021 | |
| Horizon Therapeutics Plc | $149.36 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.11 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $118.15 | 2019-2022 | |
| Astellas Pharma US INC | $102.12 | 2020-2024 | Veozah |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Archer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.